Related Experiment Video
Updated: Jun 20, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Ranolazine attenuates behavioral signs of neuropathic pain
Harry J Gould1, Colleen Garrett, Renee R Donahue
1Department of Neurology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Abstract:
Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Analgesia and Pain Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Drugs Affecting Neurotransmitter Release or Uptake
